Campuzano MG

Language: Spanish
References: 28
Page: 509-510
PDF size: 185.91 Kb.

Text Extraction

No abstract.

REFERENCES

1. Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA : the journal of the American Medical Association 1910;55:1185.

2. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972;287:155-159.

3. Peterson P, Hayes TE, Arkin CF, Bovill EG, Fairweather RB, Rock WA, Jr., et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists’ and American Society of Clinical Pathologists’ position article. Arch Surg 1998;133:134-139.

4. Wu AH. Reducing the inappropriate utilization of clinical laboratory tests. Conn Med 1997;61:15-21.

5. Wu AH, Lewandrowski K, Gronowski AM, Grenache DG, Sokoll LJ, Magnani B. Antiquated tests within the clinical pathology laboratory. Am J Manag Care 2010;16:e220-227.

6. Clinic M, Hernández J. Optimal utilization of laboratory testing. http://www.mayomedicallaboratories.com/articles/hottopics/transcripts/ 2011/11-optimal-util/index.html. 2011.

7. http://www.hfs.illinois.gov/assets/043003_podiatry_notice.pdf.

8. http://inahta.episerverhotell.net/upload/Briefs_12/12084_Biology_ of_haemostasis_disorders_bleeding_time.pdf.

9. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961;36:212-219.

10. Harrison P. Platelet function analysis. Blood Rev 2005;19:111-123.

11. Stasik CJ. Principles, Indications, and Limitations of the Platelet Function Analyzer. College of American Pathologists. 2006. Disponible en http://www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOv erride=%2Fportlets%2FcontentViewer%2Fshow&cntvwrPtlt%7BactionF orm.contentReference%7D=newspath%2F0608%2FPlatelet_Function_ Analyzer.html&_pageLabel=cntvwr.

12. Franchini M. The platelet-function analyzer (PFA-100) for evaluating primary hemostasis. Hematology 2005;10:177-181.

13. Favaloro EJ. Clinical utility of the PFA-100. Seminars in thrombosis and hemostasis 2008;34:709-733.

14. Kerenyi A, Schlammadinger A, Ajzner E, Szegedi I, Kiss C, Pap Z, et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thrombosis research 1999;96:487-492.

15. Buyukasik Y, Karakus S, Goker H, Haznedaroglu IC, Ozatli D, Sayinalp N, et al. Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. Blood Coagul Fibrinolysis 2002;13:349-353.

16. Harrison P, Robinson M, Liesner R, Khair K, Cohen H, Mackie I, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clinical and laboratory Haematology 2002;24:225-232.

17. Carcao MD, Blanchette VS, Dean JA, He L, Kern MA, Stain AM, et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. British journal of haematology 1998;101:70-73.

18. Favaloro EJ. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Seminars in thrombosis and hemostasis 2006;32:537-545.

19. Mueller T, Dieplinger B, Poelz W, Haltmayer M. Utility of the PFA- 100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/ Hemostasis 2009;15:652-659.

20. Gianetti J, Parri MS, Della Pina F, Marchi F, Koni E, De Caterina A, et al. Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction. ScientificWorldJournal 2013;2013:313492.

21. Causes of death 2008, World Health Organization, Geneva, http:// www.who.int/healthinfo/ global_burden_disease/ cod_2008_sources_ methods.pdf.

22. World Health Organization. Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva, WHO, 2009.

23. Rivera J, Lozano ML, Vicente V. In vitro changes of platelet parameters: lessons from blood banking. Methods Mol Biol 2004;273:57-72.

24. Salama ME, Raman S, Drew MJ, Abdel-Raheem M, Mahmood MN. Platelet function testing to assess effectiveness of platelet transfusion therapy. Transfus Apher Sci 2004;30:93-100.

25. Tsantes AE, Mantzios G, Giannopoulou V, Tsirigotis P, Bonovas S, Rapti E, et al. Monitoring aspirin treatment in patients with thrombocytosis: comparison of the platelet function analyzer (PFA)-100 with optical aggregometry. Thrombosis research 2008;123:100-107.

26. Minford AM, Richards EM. Excluding medical and haematological conditions as a cause of bruising in suspected non-accidental injury. Arch Dis Child Educ Pract Ed 2010;95:2-8.

27. Sharathkumar AA, Shapiro AD. Trastornos de la función plaquetaria. Federación Mundial de Hemofilia 2008;1-28.

28. Laposata M, Proytcheva MA, Rutledge JC, Stratton CW. Professional quality assurance in laboratory medicine: what about the competency of laboratory directors? Am J Clin Pathol 2010;134:706-708.